These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 32216031)
21. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R Oncology; 2022; 100(1):1-11. PubMed ID: 34670215 [TBL] [Abstract][Full Text] [Related]
22. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
23. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
24. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Guo F; Gong H; Zhao H; Chen J; Zhang Y; Zhang L; Shi X; Zhang A; Jin H; Zhang J; He Y Sci Rep; 2018 Apr; 8(1):6076. PubMed ID: 29666387 [TBL] [Abstract][Full Text] [Related]
25. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040 [TBL] [Abstract][Full Text] [Related]
26. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer. Lindner AU; Carberry S; Monsefi N; Barat A; Salvucci M; O'Byrne R; Zanella ER; Cremona M; Hennessy BT; Bertotti A; Trusolino L; Prehn JHM Int J Cancer; 2020 Nov; 147(10):2891-2901. PubMed ID: 32700762 [TBL] [Abstract][Full Text] [Related]
27. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
28. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]
29. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422 [TBL] [Abstract][Full Text] [Related]
30. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789 [TBL] [Abstract][Full Text] [Related]
31. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
32. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer. Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936 [TBL] [Abstract][Full Text] [Related]
33. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer. Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414 [TBL] [Abstract][Full Text] [Related]
34. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Li W; Qiu T; Guo L; Ying J Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915 [TBL] [Abstract][Full Text] [Related]
36. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133 [TBL] [Abstract][Full Text] [Related]
37. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501 [TBL] [Abstract][Full Text] [Related]
38. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078 [TBL] [Abstract][Full Text] [Related]
39. Mutation Status of Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662 [TBL] [Abstract][Full Text] [Related]
40. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania. Brinzan CS; Aschie M; Cozaru GC; Deacu M; Dumitru E; Burlacu I; Mitroi A Medicine (Baltimore); 2022 Oct; 101(40):e30979. PubMed ID: 36221415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]